MenAfriVac

MenAfriVac is a vaccine developed for use in sub-Saharan Africa for children and adults between 9 months and 29 years of age against meningococcal bacterium Neisseria meningitidis group A. The vaccine costs less than US$0.50 per dose.[1][2]

  1. ^ World Health Organization (November 2011). "Meningococcal vaccines. World Health Organization position paper, November 2011" (PDF). World Health Organization. Retrieved 31 January 2017.
  2. ^ World Health Organization (February 2015). "Meningococcal A conjugate vaccine: updated guidance. World Health Organization" (PDF). World Health Organization. Retrieved 31 January 2017.